Bio-Rad (BIO) delivered earnings and revenue surprises of -31.77% and +1.83%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Bio-Rad Laboratories Inc. (BIO.B) on Thursday reported a first-quarter loss of $527.1 million, after reporting a profit in the same period a ...

Rad's first quarter 2026 results showed resilience, with the company reporting revenue within its guidance. The region has ...

Bio-Rad Laboratories, Inc. (BIO) is scheduled to announce Q1 earnings results on Thursday, April 30th, after market close.

Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, today announced the ...

TheFly reported on April 7 that Citigroup lowered its rating on BIO from Buy to Neutral and reduced its price target from ...

With a market cap of $9.5 billion, Bio-Rad Laboratories, Inc. (BIO) operates in the healthcare and life sciences industry. The Hercules, California-based company develops and manufactures a wide range ...

Bio-Rad is a "picks and shovels" company in the life sciences industry, but lacks standout growth, margins, or returns, and that has been largely true for more than two decades. Recent trends in the ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based ...

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Roop K. Lakkaraju ...